Full Text View
Tabular View
No Study Results Posted
Related Studies
Extension Study on Efficacy and Safety of Deferasirox Treatment in Patients With Beta-thalassemia and Transfusional Hemosiderosis
This study has been completed.
Study NCT00171301   Information provided by Novartis
First Received: September 12, 2005   Last Updated: October 25, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Beta-thalassemia Major
Additional conditions recognized in this trial
Beta-Thalassemia
Hemosiderosis
Thalassemia
More general conditions related to this trial
Anemia
Anemia, Hemolytic
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn
Hematologic Diseases
Hemoglobinopathies
Iron Metabolism Disorders
Iron Overload
Metabolic Diseases
Interventions listed in this trial
ICL670; deferasirox
Additional drug interventions recognized in this trial
Deferasirox
More general drug interventions related to this trial
Chelating Agents
Iron Chelating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Sponsors listed in this trial
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services